Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc.

Biotechnology Research

Cambridge, Massachusetts 39,091 followers

Breaking through barriers in gene therapy and neurology

About us

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Cambridge, Massachusetts
Type
Public Company
Founded
2014
Specialties
Gene Therapy, biotechnology, adeno associated virus, Research, Parkinson's Disease, Huntington's Disease, vector engineering, SF9, Alzheimer's disease, ALS, Amyotrophic Lateral Sclerosis, Friedrich's Ataxia, SOD-1, Tauopathies, gene therapy, Neurology, Neuropharmacology, and CNS

Locations

Employees at Voyager Therapeutics, Inc.

Updates

  • We’re excited to introduce Raj Rajagovindan, who has joined Voyager as Vice President of Translational Medicine.   With over 15 years of industry experience, Raj brings extensive expertise in translational and precision medicine approaches to clinical development in Alzheimer’s disease and other neurodegenerative diseases. His work will help to further propel Voyager’s pipeline of neurogenetic medicines as they advance through clinical testing.

    • Photo of Raj Rajagovindan as we welcome him as Voyager's VP, Translational Medicine
  • Last week, Nobel Prize winner Dr. Phil Sharp joined Voyager CEO Al Sandrock for an inspiring fireside chat at our town hall. Dr. Sharp’s insights from his groundbreaking work on RNA splicing and his pivotal role in shaping the biotech industry left Voyagers awestruck. Here’s one of Dr. Sharp’s many impactful quotes: “The highest calling of what we can do is help others… You’re incredibly privileged to be in a position to take science, discover and innovate. That is a remarkably gratifying activity.” Thank you for joining us, Dr. Sharp!

    • Photo of Nobel Prize winner Phil Sharp and Voyager CEO Al Sandrock at January employee town hall.
  • Attending last month’s Massachusetts Conference for Women in Boston, members of our Women at Voyager Engage ERG heard from inspiring keynote speakers, including Caitlin Clark, Robin Roberts, Gayle King, and Oprah Winfrey, among others.      Our ERG members found the conference’s theme of #PowerInUnity directly resonated with Voyager’s own core value of Better Together: https://bit.ly/4h6ALrk. The meeting provided a unique opportunity to participate in sessions on trusting your inner voice, creating cultures of belonging that transform teams, taking charge of your career, and redefining failure as your gateway to innovation and growth. 

    • Photos from last month’s Massachusetts Conference for Women in Boston.
  • 2024 was an eventful year at Voyager. We saw important progress in our wholly-owned and partnered neurogenetic medicine pipeline, including advancement into the clinic of our anti-tau antibody (VY7523) for Alzheimer’s disease.    The Voyager community’s commitment, passion, and hard work have made this possible, and our annual Winter Recharge allows us to prioritize rest and well-being for our employees at the end of the calendar year. We are grateful to the community for your dedication and look forward to seeing you in 2025! 

    • Winter Recharge
We'll see you in 2025!
Voyager Therapeutics
  • Thank you, Kenneth Hobby of Cure SMA, for speaking at Voyager’s recent all-employee Town Hall about how treatments for spinal muscular atrophy have transformed the community. Our team was inspired by your passion and appreciated learning from the SMA community – you shared so many valuable lessons to consider as we advance our pipeline of neurogenetic medicines for SMA and other diseases of the central nervous system. https://bit.ly/3P1rKmU

    • Kenneth Hobby of Cure SMA, for speaking at Voyager’s recent all-employee Town Hall
  • We’re proud to join Life Science Cares Boston’s #NetworkofGood as a Corporate Partner! At Voyager, we’re committed to giving back to our community and are excited to start doing so with LSC Boston by packing wellness and hygiene kits for the Urban Farming Institute of Boston and Victory Programs during our upcoming town hall.    Thank you, LSC Boston, for welcoming us and for your incredible work in addressing poverty and inequality. We’re thrilled to support your mission and invest in making a meaningful impact together. 

    View organization page for Life Science Cares Boston, graphic

    11,611 followers

    We’re excited to announce that Voyager Therapeutics, Inc. has recently joined Life Science Cares Boston's Network of Good as a Corporate Partner! And they are jumping right in to giving back by packing wellness kits for Urban Farming Institute of Boston (UFI) and hygiene kits for Victory Programs as part of their town hall meeting next week. We are thrilled to have Voyager join us in helping to support the greatest needs in the community.   LSC Boston is a nonprofit that activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities. LSC Boston envisions all of our neighbors having access to basic needs, education, and opportunity. Voyager has made a community investment in LSC Boston, which helps provide funding to our 32 nonprofit partners. Thank you, Voyager, and welcome to the #NetworkofGood!

    • No alternative text description for this image
  • A highlight for many Voyagers this year has been the opportunity to connect with members of our Board of Directors. Recently, Jim Geraghty, accomplished biopharmaceutical industry leader, shared with us the many lessons he’s learned over his career, including the importance of company culture and how it drives successful strategies, the impact of senior leaders being respectful and approachable, and the value of having fun and joy at work. From supporting our employee resource groups to having fireside chats, we really appreciate how our Board has given their time to our community. 

    • Thank you for stopping by, Jim Geraghty! | Voyager Therapeutics

Similar pages

Browse jobs

Funding

Voyager Therapeutics, Inc. 6 total rounds

Last Round

Post IPO equity

US$ 100.0M

See more info on crunchbase